CliffBio
small molecule

PHOSLO

CALCIUM ACETATE

Loss of exclusivity—loss of exclusivity
CompanyFRESENIUS MEDICAL CARE RENAL THERAPIES GROUP LLC

Drug detail

Brand namePHOSLO
Active ingredientCALCIUM ACETATE
Strength667MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalApril 2001
Marketing statusDISCN

More from FRESENIUS MEDICAL CARE RENAL THERAPIES GROUP LLC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

PHOSLO patent cliff — loss of exclusivity — | CliffBio